News for Sanofi (SNY)

Sanofi (NASDAQ:SNY) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 4:00 PM ETCompany ParticipantsBrian Foard - Executive VP &...

Sanofi (SNY) boosts Beyfortus production to meet growing RSV vaccine demand ahead of 2025–2026 season.

**media[648941]**

PR NewswireNEW YORK, June 7, 2025 NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" o

Sanofi Launches 2025 Global Employee Stock Purchase Plan

**media[643889]**

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM), a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells

PR NewswirePARIS and CAMBRIDGE, Mass., June 2, 2025 Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the San

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Read more about why SNY is still a Buy.

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks will weather the storm.

**media[610770]**

**media[608627]**

Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial assistance MONTREAL, April 25, 2025 /PRNewswire/ -- The World Federation of Hemophilia (WFH) and WFH USA, together with Sanofi, through its philanthropic organization Foundation S, and Sobi, announce the signing of a contract providing support to the WFH Humanitarian Aid Program in the form of medicine donations and financial assistance for up to 5 years. This is the second renewal of the collaboration, which has been in place for more than ten years and demonstrates the partners' commitment to providing the necessary care and resources for people with hemophilia around the world.

Sanofi (NASDAQ:SNY) Q4 2024 Earnings Call Transcript Q1 2025 Earnings Conference Call April 25, 2025 7:00 AM ETCompany ParticipantsThomas Kudsk Larsen -...

The following slide deck was published by Sanofi in conjunction with their 2025 Q1 earnings call.

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%. The

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read more here.

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adu

Sanofi (SNY) stock slips as the company's asthma therapy amlitelimab fails in a Phase 2 trial, despite its plans to evaluate it in a Phase 3 trial. Read more here.